


CLAIMS

We claim:

1. An amorphous form of 5-fluoro-2-(6-fluoro-2-methyl-1H-benzimidazol-1-yl)-N-[4-(trifluoromethyl)phenyl]pyrimidine-4,6-diamine, having the formula of Compound A:



Compound A.

2. The form of claim 1, wherein the amorphous form of Compound A is at least 90% amorphous.
3. The form of claim 2, wherein the amorphous form of Compound A is a substantially pure amorphous form.
4. An amorphous solid dispersion comprising, the amorphous form of any of claims 1, 2 or 3 and a stabilizing polymer.
5. The dispersion of claim 4, wherein the stabilizing polymer is selected from polyvinylpyrrolidone or hydroxypropylmethylcellulose acetate succinate.
6. The dispersion of claim 5, wherein the stabilizing polymer is hydroxypropylmethylcellulose acetate succinate.
7. The dispersion of claim 4, wherein the amount by weight of Compound A to the amount by weight of the stabilizing polymer is in a ratio of between about 5:95 to about 60:40.
8. The dispersion of claim 7, wherein the amount by weight of Compound A to the amount by weight of the stabilizing polymer is in a ratio of between about 10:90 to about 40:60.
9. The dispersion of claim 4, wherein the dispersion is obtained by solvent casting of a solution comprising Compound A and the stabilizing polymer.

10. The dispersion of claim 4, wherein the dispersion is obtained by spray drying a solution comprising Compound A and the stabilizing polymer.
11. A process for preparing the dispersion of claim 4, comprising:
 - (a) dissolving Compound A and one or more stabilizing polymers in a solvent to form a solution; and,
 - (b) drying the solution to form the dispersion of claim 4.
12. The process of claim 11, wherein the solvent is selected from acetone, methyl ethyl ketone, dichloromethane, or methanol.
13. The process of claim 11, wherein the solution is dried by solvent casting to form the dispersion of claim 4.
14. The process of claim 11, wherein the solution is dried by spray drying to form the dispersion of claim 4.
15. A pharmaceutical composition comprising, an admixture of the dispersion of claim 4 and one or more pharmaceutically acceptable excipients.
16. The pharmaceutical composition of claim 15, wherein the one or more pharmaceutically acceptable excipients are selected from a diluent, a disintegrant, a lubricant or a surfactant.
17. The pharmaceutical composition of claim 16, wherein the surfactant is selected from sodium lauryl sulfate or Poloxamer 407.
18. A process for preparing the pharmaceutical composition of claim 15 comprising,
 - (a) grinding the dispersion of claim 4 to form a solid dispersion powder;
 - (b) admixing the powder with one or more pharmaceutically acceptable excipients to form an admixture;
 - (c) granulating the admixture to form a granulate; and,
 - (d) tableting or encapsulating the granulate to form tablets or capsules, respectively.